

6 December 2022

Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000

**Bod Australia Limited (ASX: BOD)
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)**

Bod Australia Limited (ASX:BOD) ACN 601 225 441 (the **Company** or **Bod**) has on 5 December 2022 issued 1,875,000 shares in the Company pursuant to the share placement which was announced to ASX on 1 September 2022 and for which shareholder approval was obtained at the Company's Annual General Meeting held on 28 November 2022.

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**) that:

1. the Company issued 1,875,000 ordinary shares in the Company without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice the Company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to Bod; and
 - b. sections 674 and 674A of the Act;
3. there is no information that is 'excluded information' (within the meaning of section 708A(7) and section 708A(8) of the Act).

Authorised for release by the Company Secretary of Bod Australia Limited.

ENDS

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033

About Bod Australia

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information on BOD please visit <https://bodscience.com/>

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 T +61 2 9199 5018 E info@bodscience.com W bodscience.com